Latest news and video coverage curated from trusted media outlets
Mayo Clinic Blood Donor program launches "Giving for Garrett" campaign
Local Chiefs fan selected as NFL Fan of the Year nominee
SD firefighters rally around firefighter battling cancer
Credit: ABC 10 News | San Diego Duration: 02:05Published
11092020 Lung cancer awareness
Credit: WTVQ Lexington, KYPublished
'Light The Night' Virtual Walk
Credit: KTNV Channel 13 Las Vegas Duration: 05:16Published
Jeff Bridges 'appreciating mortality' after cancer diagnosis
Credit: Cover Video STUDIO Duration: 00:52Published
Dad living with cancer does 176,200 pushups
Credit: USA Today Kind (International) Duration: 00:57Published
NEWS OF THE WEEK: Jeff Bridges diagnosed with lymphoma
Credit: Cover Video STUDIO Duration: 00:46Published
Scotts Valley High School keeps tradition alive with drive-thru haunted house
Credit: KSBW Duration: 02:01Published
WCBI NEWS at 10 - 10/21/2020
Jeff Bridges Reveals He Has Been Diagnosed with Lymphoma and Is Starting Treatment
Credit: People Duration: 01:00Published
Jeff Bridges Has Lymphoma—Here's What to Know About This Form of Cancer, and What His Trea
Credit: Health.com Duration: 01:06Published
Jeff Bridges Reveals Lymphoma Cancer Diagnosis In Heart Breaking Post
Credit: Hollywood Life Duration: 01:53Published
Jeff Bridges Reveals He's Been Diagnosed With Lymphoma | THR News
Credit: THR News Duration: 01:21Published
Jeff Bridges Diagnosed With Lymphoma
Credit: ETCanada Duration: 01:17Published
Actor Jeff Bridges has announced he's been diagnosed with lymphoma
Credit: USA Today Entertainment (Domesti Duration: 00:58Published
Jeff Bridges Starting Treatment After Being Diagnosed With Lymphoma
Credit: CBS 2 New York Duration: 00:30Published
'The prognosis is good': Jeff Bridges diagnosed with lymphoma
Credit: Bang Media International Limited Duration: 01:19Published
Jeff Bridges Is Diagnosed With Lymphoma Cancer
Credit: Wochit Duration: 00:35Published
Baltimore Buzz: Jeff Bridges Has Lymphoma
Credit: WJZ Baltimore Duration: 01:38Published
Jeff Bridges diagnosed with lymphoma
Credit: Cover Video STUDIO Duration: 00:46Published
4-Year-old Miami Boy Battling Acute Lymphoblastic Leukemia Gets Special Parade
Credit: CBS4 Miami Duration: 01:42Published
WCBI NEWS at 10 - 10/10/2020
WCBI New at Six - 10/10/2020
You Might Like
Global Gene Therapy Market Report 2020-2027: Market is Projected to Reach a Revised $3.3 BillionDublin, Nov. 27, 2020 (GLOBE NEWSWIRE) -- The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to *ResearchAndMarkets.com's* offering. *In a Major Setback to the..
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic SyndromeSHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering,..
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEMNEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM). Such..
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients· Studies reinforce clonoSEQ as standard of care in minimal residual disease (MRD) across eight disease states· Real-world evidence shows treatment decisions based on precise MRD measurement directly..
Silicon Therapeutics Announces Dosing of First Patient in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or LymphomaBOSTON--(BUSINESS WIRE)-- #AI--Silicon Therapeutics announces treatment of first patient with its therapeutic candidate SNX281 in a Phase 1 clinical trial.
Lucintel Anticipates that North America Will be the Fastest Growing Region in the Cancer Biomarker Market*DALLAS, TX / ACCESSWIRE / November 23, 2020 / *According to a new market report published by Lucintel, the future of the cancer biomarker market looks promising with opportunities in the diagnostics,..
SinoMab Commenced Construction of its China HeadquartersHONG KONG, Nov 23, 2020 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research,..
ESMO ASIA Congress 2020 | CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLCSUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO)..
Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and..
Jeff Bridges ‘Isn’t Ready To Throw In The Towel’ — Inside His Brave Cancer BattleFans were shocked and heartbroken when Jeff Bridges took to Twitter in late October to reveal he’d been diagnosed with lymphoma at age 70. “Although it is a serious disease, I feel fortunate that I..
Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock ExchangeHONG KONG, Nov. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leader in discovery, development and commercialization of innovative cancer medicines, today..
ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaLAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent..
CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in DecemberSHANGHAI, Nov. 20, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company, today announced that data from its global multiple myeloma program will be presented, including..
Cricket: Canterbury seamer Andrew Hazeldine to miss domestic summer due to Hodgkin lymphoma diagnosisA New Zealand first-class cricketer's career has been put on hold after being diagnosed with cancer.Canterbury left-arm fast bowler Andrew Hazeldine, 26, was told in September he had Hodgkin lymphoma..
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bio-Path..
Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of MedicineNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced results from the Phase 3 CROWN trial of LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI®..
Global Gene Therapy IndustryIn a Major Setback to the Healthcare System, Non-COVID-19 Care Delivery Bears the Brunt of the Pandemic. Gene Therapy Market Slumps by -13. 6%. The global market for Gene Therapy is expected to decline..
Hemogenyx Pharmaceuticals plc announces Financing Facility of up to £60 Million*NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT..
Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 MillionSAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today..
Oncternal Therapeutics Announces $20.0 Million Bought Deal OfferingSAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today..
Kazia Therapeutics sets sights on advancing near-term paxalisib commercialisation plansKazia Therapeutics Ltd (ASX:KZA) enjoyed a productive September quarter, advancing the development of its product candidates, according to chief executive officer Dr James Garner. He said: “The..
Axiom Presenting “Simplifying the Complex Data and Operational Awareness Needs of Oncology Studies Using Unified eClinical Tech” at Clinical Operations in Oncology Trials USA 2020: A Virtual ExperienceTORONTO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, is a presenting sponsor and exhibitor at Clinical..
Preserving Courtroom And Verdict Integrity – OpEdBig Media, Big Tech, Big Academia, the Deep State and the Cancel Culture clearly aligned with the Democrat Party, to resist, block, impede and impeach a duly elected President Trump, during and after..
RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications-Evidence of Monotherapy and Combination Activity in Charged Tumor Types- -Company Advances Several Cohorts into Phase 2 Expansions- -Conference Call and Webcast to be Held at 8:30 a.m. ET..
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN If approved by the European Commission, ELZONRIS will be the first approved treatment for patients..
VolitionRx ends 3Q with $21M in cash as it prepares to launch Nu.Q Vet Cancer Screening TestVolitionRx Limited (NYSEAMERICAN:VNRX) said Thursday it ended its third quarter with cash and cash equivalents of about $21 million as it prepares to launch its first product -- the Nu.Q Vet Cancer..
Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update*- Continued Advancement of XCART™ Platform Towards an IND Filing and Phase 1 Study* *- Leveraging Partnerships With Leading Global Academic Institutions, Including Scripps..
Insights on the Worldwide Nuclear Medicine Market to 2025 - Featuring GE Healthcare, Siemens Healthineers & Rotem Industries Among OthersDublin, Nov. 13, 2020 (GLOBE NEWSWIRE) -- The "Global Nuclear Medicine Market By Therapy (Radioactive Iodine, Radioactive Antibodies, Others), By Type (SPECT, PET, Alpha-emitters, Beta-emitters,..
Bio-Path Holdings Reports Third Quarter 2020 Financial ResultsConference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™..
TG Therapeutics to Participate in the Jefferies Virtual London Healthcare ConferenceFireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S...
Vision 20 Reviews - Groundbreaking New Report on Vision 20 for EyesightVision 20 by Zenith Labs is an eye care supplement that, by its ingredients, tries to protect your eyesight. Houston, TX , Nov. 13, 2020 (GLOBE NEWSWIRE) -- Vision 20 is a dietary supplement that..
EMA grants PRIME tag to Innate Pharma's lacutamab for T-cell lymphoma
Kiadis announces presentations at the 2020 ASH Annual Meeting and Exposition*Amsterdam, The Netherlands, November 13, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS)*, a clinical-stage biopharmaceutical company developing..
Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in Sézary SyndromePriority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options MARSEILLE, France, Nov. 13, 2020 (GLOBE NEWSWIRE) --..
Soligenix, Inc. to Present at the virtual Fall Investor Summit on November 16th-18th*NEW YORK, NY / ACCESSWIRE / November 12, 2020 /* Soligenix, Inc. (NASDAQ:SNGX),* *a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where..
CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC· Currently, there is no anti-PD-L1 monoclonal antibody approved for stage IV NSCLC in China · An oral presentation of specific clinical trial data of CS1001-302 study will be given at ESMO Asia..
MorphoSys Reports Nine Months and Third Quarter 2020 Results*Conference call and webcast (in English) to be held on November 12, 2020 at 2:00pm CET (1:00pm GMT/8:00am EST)* *PLANEGG / MUNICH, GERMANY/ ACCESSWIRE / November 11, 2020 / *MorphoSys AG (FSE:MOR)..
Also reported by •EQS Group
MorphoSys and Cherry Biolabs Announce Licensing of Hemibody Technology*The parties signed a multi-target exclusive licensing agreement for application of Cherry Biolabs' Hemibody technology * *Combination with MorphoSys' antibody know-how enables discovery and..
Also reported by •EQS Group
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab*MONROVIA, CA, PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / November 11, 2020 /* Xencor (XNCR), MorphoSys AG (FSE:MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) and Incyte (INCY)..
Also reported by •Business Wire •EQS Group
CAP and ASCP Announce Laboratory Workup of Lymphoma in Adults GuidelineCHICAGO--(BUSINESS WIRE)-- #pathologists--The CAP and the ASCP have released a new evidence-based clinical practice guideline, “Laboratory Workup of Lymphoma in Adults.”
NA Proactive news snapshot: Gevo, CleanSpark, KushCo Holdings, Water Tower Research, LeanLife Health, ElectraMeccanica UPDATE …Gevo Inc (NASDAQ:GEVO), citing a strong balance sheet and available cash, said Tuesday it expects to pay off its entire outstanding secured debt balance of $12.7 million by year’s end. The company..
CoImmune, Inc. Announces Closing of $45 Million Series A FinancingDURHAM, N.C., Nov. 10, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications,..
NA Proactive news snapshot: African Gold Group, Inc, Predictmedix Inc, Royal Road Minerals Limited, VolitionRx Limited, Melkior Resources Inc, Nomad Royalty UPDATE …African Gold Group, Inc (CVE:AGG) (ASX:A1G) (OTCMKTS:AGGFF) Tuesday announced that its team is helping local stakeholders keep key roads and infrastructure open in Mali, West Africa, in what has been..
VolitionRx says veterinary oncology experts contribute to report ahead of Nu.Q Vet Cancer Screening Test launchVolitionRx Limited (NYSEAMERICAN:VNRX) announced a report Tuesday with contributions from four global leaders in veterinary oncology ahead of the expected launch of its first animal-test product -- the..
Innovative Cellular Therapeutics to Present CoupledCAR® Solid Tumor CAR-T Clinical Data at Upcoming Scientific MeetingsROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T..
Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress· Established license and strategic collaboration with Roivant Sciences - $60 million in upfront consideration and up to $2 billion in future milestones · Recognized milestone payment from Genentech..